366 related articles for article (PubMed ID: 27428710)
1. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
3. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Gamerith G; Mildner F; Merkel PA; Harris K; Cooney L; Lim N; Spiera R; Seo P; Langford CA; Hoffman GS; St Clair EW; Fervenza FC; Monach P; Ytterberg SR; Geetha D; Amann A; Wolf D; Specks U; Stone JH; Kronbichler A
Ann Rheum Dis; 2023 Feb; 82(2):253-261. PubMed ID: 35973802
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
5. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Hillion S; Konig MF; Moura MC; Hummel AM; Carmona E; Peikert T; Fervenza FC; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; Brunetta P; St Clair EW; Harris KM; Stone JH; Grandi G; Pers JO; Specks U; Cornec D
Arthritis Rheumatol; 2023 May; 75(5):736-747. PubMed ID: 36281741
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
9. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
Holding S; Fisher VJ; Abuzakouk M
Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
[TBL] [Abstract][Full Text] [Related]
10. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
[TBL] [Abstract][Full Text] [Related]
11. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
13. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
[TBL] [Abstract][Full Text] [Related]
14. Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.
Cao Y; Tian Z; Li W; Ma L; Yu Y; Ren W
J Rheumatol; 2014 May; 41(5):916-22. PubMed ID: 24634200
[TBL] [Abstract][Full Text] [Related]
15. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
16. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Ann Rheum Dis; 2006 Nov; 65(11):1484-9. PubMed ID: 16504995
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
19. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
20. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
